Soft substrates drive optimal differentiation of human healthy and dystrophic myotubes.

The in vitro development of human myotubes carrying genetic diseases, such as Duchenne Muscular Dystrophy, will open new perspectives in the identification of innovative therapeutic strategies. Through the proper design of the substrate, we guided the differentiation of human healthy and dystrophic myoblasts into myotubes exhibiting marked functional differentiation and highly defined sarcomeric organization. A thin film of photo cross-linkable elastic poly-acrylamide hydrogel with physiological-like and tunable mechanical properties (elastic moduli, E: 12, 15, 18 and 21 kPa) was used as substrate. The functionalization of its surface by micro-patterning in parallel lanes (75 microm wide, 100 microm spaced) of three adhesion proteins (laminin, fibronectin and matrigel) was meant to maximize human myoblasts fusion. Myotubes formed onto the hydrogel showed a remarkable sarcomere formation, with the highest percentage (60.0% +/- 3.8) of myotubes exhibiting sarcomeric organization, of myosin heavy chain II and alpha-actinin, after 7 days of culture onto an elastic (15 kPa) hydrogel and a matrigel patterning. In addition, healthy myotubes cultured in these conditions showed a significant membrane-localized dystrophin expression. In this study, the culture substrate has been adapted to human myoblasts differentiation, through an easy and rapid methodology, and has led to the development of in vitro human functional skeletal muscle myotubes useful for clinical purposes and in vitro physiological study, where to carry out a broad range of studies on human muscle physiopathology.

[1]  R. Parks,et al.  Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  M. Sampaolesi,et al.  New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials. , 2007, Trends in molecular medicine.

[3]  J. Hyllner,et al.  Human embryonic stem cell technologies and drug discovery , 2009, Journal of cellular physiology.

[4]  U. Müller,et al.  Beta1 integrins regulate myoblast fusion and sarcomere assembly. , 2003, Developmental cell.

[5]  P. Vliet,et al.  Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: an in vitro model for studying human cardiac physiology and pathophysiology , 2009, Nature Protocols.

[6]  B. Sacchetti,et al.  Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells , 2007, Nature Cell Biology.

[7]  A. Emery,et al.  The muscular dystrophies , 2002, The Lancet.

[8]  L. Griffith,et al.  Capturing complex 3D tissue physiology in vitro , 2006, Nature Reviews Molecular Cell Biology.

[9]  John M. Haynes,et al.  Embryonic stem cells as a source of models for drug discovery , 2007, Nature Reviews Drug Discovery.

[10]  George J Christ,et al.  The influence of electrospun aligned poly(epsilon-caprolactone)/collagen nanofiber meshes on the formation of self-aligned skeletal muscle myotubes. , 2008, Biomaterials.

[11]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[12]  Aiping Du,et al.  How to build a myofibril , 2006, Journal of Muscle Research & Cell Motility.

[13]  S. Sen,et al.  Matrix Elasticity Directs Stem Cell Lineage Specification , 2006, Cell.

[14]  Elisa Cimetta,et al.  Production of arrays of cardiac and skeletal muscle myofibers by micropatterning techniques on a soft substrate , 2009, Biomedical microdevices.

[15]  F. Schöck,et al.  Zasp is required for the assembly of functional integrin adhesion sites , 2007, The Journal of cell biology.

[16]  Amy H. Herrera,et al.  N-RAP scaffolds I-Z-I assembly during myofibrillogenesis in cultured chick cardiomyocytes , 2004, Journal of Cell Science.

[17]  M. Wakelam.  The fusion of myoblasts. , 1985, The Biochemical journal.

[18]  H. Blau,et al.  Self-renewal and expansion of single transplanted muscle stem cells , 2008, Nature.

[19]  E. Olson,et al.  Signaling pathways in skeletal muscle remodeling. , 2006, Annual review of biochemistry.

[20]  D. Kohane,et al.  Engineering vascularized skeletal muscle tissue , 2005, Nature Biotechnology.

[21]  Daniel J Garry,et al.  Muscle stem cells in development, regeneration, and disease. , 2006, Genes & development.

[22]  Adam J. Engler,et al.  Myotubes differentiate optimally on substrates with tissue-like stiffness , 2004, The Journal of cell biology.

[23]  D. Bredt.  Knocking signalling out of the dystrophin complex , 1999, Nature Cell Biology.

[24]  M. Rudnicki,et al.  Cellular and molecular regulation of muscle regeneration. , 2004, Physiological reviews.

[25]  David J. Mooney,et al.  Growth Factors, Matrices, and Forces Combine and Control Stem Cells , 2009, Science.

[26]  S. Soker,et al.  Optimization of human skeletal muscle precursor cell culture and myofiber formation in vitro. , 2009, Methods.

[27]  P. Iversen,et al.  Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD , 2006, Gene Therapy.

[28]  M. Zatz,et al.  Human multipotent adipose‐derived stem cells restore dystrophin expression of Duchenne skeletal‐muscle cells in vitro , 2008, Biology of the cell.

[29]  Jill L. Humston,et al.  Dystrophin is a microtubule-associated protein , 2009, The Journal of cell biology.

[30]  F. Schöck,et al.  The initial steps of myofibril assembly: integrins pave the way , 2009, Nature Reviews Molecular Cell Biology.

[31]  Giulio Cossu,et al.  Electrospun degradable polyesterurethane membranes: potential scaffolds for skeletal muscle tissue engineering. , 2005, Biomaterials.

[32]  M. Rudnicki,et al.  Niche regulation of muscle satellite cell self-renewal and differentiation. , 2008, Cell stem cell.